Axsome Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual report, not a standalone Q4 report; quarterly figures are noted separately below. Axsome is a clinical-stage CNS biopharmaceutical company with no approved products and no product revenue.
Business context and pipeline
The company’s five principal candidates target major depressive disorder (MDD), Alzheimer’s disease agitation, migraine, narcolepsy, fibromyalgia, and other CNS conditions. At year-end, Axsome reported it had submitted an NDA for AXS-05 for MDD and planned an NDA submission for AXS-07 for acute migraine. AXS-05 was in a Phase 3 trial for Alzheimer’s agitation; a Phase 3 narcolepsy trial for AXS-12 was planned. The company relies on third-party manufacturers and intends to build a U.S. commercial operation if products are approved.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $70.2 million | $53.6 million |
| General and administrative expense | $28.9 million | $13.6 million |
| Total operating expenses | $99.1 million | $67.2 million |
| Net loss | $102.9 million | $68.3 million |
| Net loss per share, basic and diluted | $2.77 | $2.01 |
| Net cash used in operating activities | $78.5 million | $46.4 million |
No revenue or positive profit was reported; therefore, operating margins are not meaningful. Cash and cash equivalents were $183.9 million at December 31, 2020, down from $220.0 million a year earlier. Total assets were $186.1 million, total liabilities $72.3 million, and stockholders’ equity $113.8 million. The company reported $50.0 million in outstanding loan principal, carried at $48.3 million net of debt discount and related items. Cash flow from financing was $42.4 million, including $50.0 million of Hercules loan proceeds and $14.1 million net proceeds from at-the-market stock sales, offset in part by repayment of $21.7 million of prior debt.
Management said existing cash and committed Hercules facility capital were expected to fund planned operations, including potential launches of AXS-05 and AXS-07, into at least 2024. This is an estimate dependent on operating assumptions and access to conditional loan tranches, not a guarantee.
Changes versus comparable periods and unusual items
- Net loss increased by $34.6 million year over year; operating cash use rose by $32.1 million.
- R&D expense increased $16.6 million, reflecting clinical trials, NDA-preparation work, and a $10.2 million Pfizer license charge, including $7.2 million noncash stock consideration.
- G&A expense increased $15.3 million, primarily due to higher stock-based compensation and commercial-function build-out. Stock-based compensation was $14.8 million, compared with $6.1 million in 2019.
- The company recorded a $1.2 million loss on extinguishment of its prior SVB loan after refinancing with Hercules.
- For Q4 2020, unaudited quarterly data show operating expenses of $27.7 million and net loss of $29.2 million, versus $24.4 million and $24.8 million, respectively, in Q4 2019.
Outlook, commentary and principal risks
Management expected expenses and losses to continue as development, regulatory, and potential commercialization activities expand. The company has not yet demonstrated product approval or commercial sales, and profitability depends on successful development, regulatory approval, market acceptance, reimbursement, and commercialization.
- Regulatory and clinical: FDA review may require additional evidence or studies; positive trial results and expedited designations do not ensure approval. AXS-05 did not meet the primary endpoint in the STRIDE-1 treatment-resistant depression trial, despite positive secondary findings.
- Financing and debt: The Hercules facility carries a stated rate of at least 9.15% under its terms, is secured by substantially all assets including intellectual property, and includes milestone-dependent borrowing and future covenants. Default could accelerate repayment.
- Commercial execution: Axsome has no commercialization history or established sales infrastructure; uptake, pricing, coverage, and reimbursement are uncertain, and competition includes established therapies and lower-cost generics.
- Operations and COVID-19: The company depends on CROs and contract manufacturers. COVID-19 could disrupt trial enrollment, operations, inspections, or regulatory timelines; management said it had not significantly affected trial progress to date, while future effects remained uncertain.
- Other exposures: Patent challenges, third-party intellectual-property claims, product safety or liability, healthcare regulation, and dependence on licenses are material risks. The Pfizer agreement includes up to $323 million in potential milestones plus royalties. AXS-05 licenses from Antecip, an entity owned by the CEO and board chair, require royalties on future sales and present a related-party conflict risk.
The company reported no material pending legal proceedings. Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2020; the financial statements received an unqualified audit opinion.
Investor facts to verify
- Current FDA status, review timing, and any additional requirements for the AXS-05 MDD NDA; confirm the status and timing of the planned AXS-07 NDA.
- Whether clinical development milestones for AXS-05 in Alzheimer’s agitation and AXS-12 in narcolepsy are met, and how the STRIDE-1 result affects the depression opportunity.
- Cash burn, cash balance, remaining availability and conditions under the Hercules facility, and the company’s updated runway assumptions.
- Potential launch costs, commercial readiness, payer access, pricing, and market uptake if either lead candidate is approved.
- Future financial obligations under the Pfizer and Antecip agreements, including milestone, royalty, and related-party terms.